160%

C-Major is aiming to bring to market a unique patented medical device, designed to prevent needle-stick injuries and the subsequent risk of illnesses such as HIV and Hepatitis. The company’s auto-retraction technology aims to disrupt the $5.5bn safety syringe market, which is growing at 9% each year.

  • £1m+ raised to date via Innovate UK grants and equity investment
  • Backed by the UK Innovation Seed Fund
  • Worldwide patents secured for innovative auto-retraction technology
  • Non-Exec Directors come with direct relevant safe syringe expertise

Idea

A needle-stick injury (NSI) occurs when a needle used on a patient cuts someone else’s skin. A global problem, over 2m people suffer a NSI every year and are at risk of contracting serious blood-borne viruses such as Hepatitis and HIV.

The most effective existing solutions are auto-retracting syringes where stored energy is used to retract the needle as quickly and safely as possible. However, when the needle springs back, it can result in blood splatter, meaning the blood (and any viruses it contains) can spread easily to others. As such, these solutions are used only for injections and not for aspirating (taking blood).

Since starting in 2018, C-Major has undertaken a number of user trials. Our “Controlled Helical Retraction Device” aims to be the first auto-retracting technology on the market for blood collection. The device contains a ‘helical track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘sealed port’ to minimise splatter. This technology is fully patented in target markets and, upon securing regulatory approval, has a broad range of applications.

With the safety syringe market expected to be worth $8.4bn by 2024, we are now raising funds to complete the design for manufacture and assembly process ahead of a Series A round in 2021.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the C-Major pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investing in start-ups and early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Crowdcube is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. You will only be able to invest via Crowdcube once you are registered as sufficiently sophisticated. Please click here to read the full Risk Warning.

Crowdcube is authorised and regulated by the Financial Conduct Authority (FCA) and the Comisión Nacional del Mercado de Valores (CNMV). This page has been approved by Crowdcube. Pitches for investment are not offers to the public and investments can only be made by members of crowdcube.com on the basis of information provided in the pitches by the companies concerned. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

C-Major has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.